Austin, TX, Nov. 14, 2023 (GLOBE NEWSWIRE) — QSAM Biosciences Inc. (OTCQB: QSAM), a company developing therapeutic radiopharmaceuticals for the treatment of primary and secondary bone cancer and related conditions, has signed a non-binding term sheet (the “Term Sheet”) with Telix Pharmaceuticals (US) Inc., a subsidiary of Telix Pharmaceuticals Limited…Read More
QSAM Biosciences Signs Term Sheet to be Acquired by Telix Pharmaceuticals Receives 2 Million PreClosing Collaboration and Option Fee
